Contineum Therapeutics Class Stock Probability of Future Stock Price Finishing Over 14.30
| CTNM Stock | 14.30 0.14 0.97% |
Closest to current price Contineum long PUT Option Payoff at Expiration
Contineum | Build AI portfolio with Contineum Stock |
Contineum Therapeutics Target Price Odds to finish over 14.30
The tendency of Contineum Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 14.30 | 90 days | 14.30 | about 9.25 |
Based on a normal probability distribution, the odds of Contineum Therapeutics to move above the current price in 90 days from now is about 9.25 (This Contineum Therapeutics Class probability density function shows the probability of Contineum Stock to fall within a particular range of prices over 90 days) .
Contineum Therapeutics Price Density |
| Price |
Predictive Modules for Contineum Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Contineum Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Contineum Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Contineum Therapeutics is not an exception. The market had few large corrections towards the Contineum Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Contineum Therapeutics Class, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Contineum Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.56 | |
β | Beta against Dow Jones | -0.31 | |
σ | Overall volatility | 1.66 | |
Ir | Information ratio | 0.1 |
Contineum Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Contineum Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Contineum Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Contineum Therapeutics had very high historical volatility over the last 90 days | |
| Net Loss for the year was (42.26 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Contineum Therapeutics generates negative cash flow from operations | |
| Contineum Therapeutics has a frail financial position based on the latest SEC disclosures | |
| About 62.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Disposition of 400 shares by Daniel Lorrain of Contineum Therapeutics at 1.01 subject to Rule 16b-3 |
Contineum Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Contineum Stock often depends not only on the future outlook of the current and potential Contineum Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Contineum Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 19.4 M | |
| Cash And Short Term Investments | 204.8 M |
Contineum Therapeutics Technical Analysis
Contineum Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Contineum Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Contineum Therapeutics Class. In general, you should focus on analyzing Contineum Stock price patterns and their correlations with different microeconomic environments and drivers.
Contineum Therapeutics Predictive Forecast Models
Contineum Therapeutics' time-series forecasting models is one of many Contineum Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Contineum Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Contineum Therapeutics
Checking the ongoing alerts about Contineum Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Contineum Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Contineum Therapeutics had very high historical volatility over the last 90 days | |
| Net Loss for the year was (42.26 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Contineum Therapeutics generates negative cash flow from operations | |
| Contineum Therapeutics has a frail financial position based on the latest SEC disclosures | |
| About 62.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Disposition of 400 shares by Daniel Lorrain of Contineum Therapeutics at 1.01 subject to Rule 16b-3 |
Check out Contineum Therapeutics Analysis, Contineum Therapeutics Valuation, Contineum Therapeutics Correlation, Contineum Therapeutics Hype Analysis, Contineum Therapeutics Volatility, Contineum Therapeutics Price History as well as Contineum Therapeutics Performance. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Will Pharmaceuticals sector continue expanding? Could Contineum diversify its offerings? Factors like these will boost the valuation of Contineum Therapeutics. Projected growth potential of Contineum fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Contineum Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Contineum Therapeutics requires distinguishing between market price and book value, where the latter reflects Contineum's accounting equity. The concept of intrinsic value - what Contineum Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Contineum Therapeutics' price substantially above or below its fundamental value.
It's important to distinguish between Contineum Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Contineum Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Contineum Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.